07:32 AM EST, 11/12/2025 (MT Newswires) -- Microbix Biosystems ( MBXBF ) said Wednesday Sekisui Diagnostics will use Microbix's third-party quality assessment products to support the U.S. commercialization of Sekisui's molecular point-of-care assay for diagnosis of COVID/Flu A/Flu B.

The test is being made available in the U.S. under an Emergency-Use Authorization from the U.S. Food and Drug Administration, a statement said.